Company intelligence / Profile preview

GeneVentiv Therapeutics

Raleigh, North Carolina, United Statesgeneventiv.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GeneVentiv's lead program GENV-HEM (AAV8.FVa) has demonstrated therapeutic efficacy and safety in preclinical studies and received Orphan Drug Designation from the FDA for Hemophilia A and B with or without inhibitors[4]

Therapeutic areas: Rare DiseasesHematology
Modalities: AAV-based gene therapy
Industry: Biotech

Drug pipeline

2 assets

GENV-HEM

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

ReciBioPharm (for AAV manufacturing)[4]

Beyond the preview

Go deeper on GeneVentiv Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GeneVentiv Therapeutics.

Explore the full profile